Thompson Peter A.

Director Thompson sells ~293K shares over three days for $13.4M as stock rallies off lows but trails 52-week high.

Director Thompson Peter A. has sold nearly 293,000 shares totaling $13.4 million across three days in early May, representing his third consecutive wave of open-market sales in the trailing 36-month window. The timing is notable: the stock has rallied roughly 20% over the past three months and currently trades just below its 52-week high, yet the company remains unprofitable with ongoing quarterly losses. His prior sales at this ticker show mixed results—roughly half were well-timed exits that preceded stock declines, while the other half saw the stock rise afterward, suggesting inconsistent predictive value. The scale of this sale is material relative to his prior activity, though the unprofitable company's fundamentals and the stock's proximity to recent highs could suggest he is trimming holdings rather than expressing concern about near-term direction.

Director Thompson Peter A. sold 55,345 shares ($2.5M) at $44.67–$44.68 on Apr 17–18; holds 2.96M shares post-sale; stock now $41.79.

Thompson Peter A. executed 2 separate sales totaling 55,345 shares for $2,472,342.92 at a blended average price of $44.67, representing a -1.8% reduction in his 3.02M-share holdings. The sales occurred on 2026-04-17 and 2026-04-18 at transaction prices of $44.68 and $44.52 respectively—both near the 52-week high of $45.24 and substantially above the current price of $41.79 (-7.6% from the high). At SION specifically, Thompson has executed 5 prior trades in the past 2 months (3 sells on 2026-04-16, 2026-04-15, 2026-04-14; 2 earlier sells on 2026-02-03 and 2026-02-02), with measured 30-day returns of -22.5% and -22.4% following those February sales, indicating prior sales at this ticker have not preceded gains. The company reported a net loss of $-20,278,000.00 in its most recent full fiscal year, signaling ongoing unprofitability. This clustering of sales near the 52-week highs—combined with the company's negative earnings—and prior underperformance of same-ticker sales merit investor attention to the director's confidence in near-term prospects.

Director Peter A. Thompson sold 510,583 shares ($22.9M) across 3 days at $44.51–$45.34 as stock hits 52-week high.

Thompson Peter A. (Director) executed three separate sales totaling 510,583 shares for $22,945,043.50 between April 14–16, 2026, at prices ranging from $44.51 to $45.34 (blended average $44.94). The sale occurred as the stock reached its 52-week high of $45.24 (current price +0.0% from that peak), following a sharp 26.2% gain over the prior 30 days. Despite the large dollar value, the sales represent a 14.5% reduction in his post-transaction holdings (3.02M shares remain from 3.53M), preserving a substantial position. His same-ticker track record at SION shows 5 prior sales, with 3 of 3 prior sales where 90-day outcomes were measurable proving well-timed (stock declined afterward), though his most recent two SION sales on 2026-02-02 and 2026-02-03 show 30-day declines of -22.4% and -22.5% respectively (longer-term outcomes not yet available). The company remains unprofitable with net income of $-20,278,000.00 over its most recent full fiscal year, and the director's timing coincides with the stock at cyclical resistance.

Director Peter A. Thompson sold 30,953 shares (31.0K shares) for $1,379,865.84 across two transactions at $44.57–$44.58.

Thompson executed 2 separate sales totaling 30,953 shares (31.0K shares) for $1,379,865.84, reducing his holdings by 0.9% to 3,530,702 shares (3.53M shares) post-transaction. The sales occurred at $44.57 on 2026-02-02 and $44.58 on 2026-02-03, near the top of the 52-week range ($7.66–$44.48). At the current price of $41.32, the stock has declined 7.1% from its 52-week high, placing the transaction prices well above current levels. His prior trades at SION show a pattern of 4 consecutive sells in late November and December 2025 (each with near-flat or negative 30-day returns), followed by this larger sale in early February 2026. His cross-ticker track record shows that 16 prior sells averaged +13.1% over 30 days and +49.3% over 90 days (16.67% well-timed rate), indicating his sell timing has historically trailed price appreciation. The company is unprofitable (net income $-20.3M) and carries a market cap of $1.8B; the timing and scale of this director-level liquidation warrant investor attention.

Director Thompson sells 33,356 shares of SION at $44.55; stock now $42.81, down 3.5% from 52-week high

Director Peter A. Thompson sold 33,356 shares at $44.55 on 2025-12-24, reducing his holdings by 0.9% to 3,561,655 shares while retaining substantial position. At current price of $42.81, the stock has declined 1.7% in 30 days and is -3.5% from its 52-week high of $44.38, suggesting the sale occurred near recent peak levels. His cross-ticker track record shows 15 prior sells with an average 90-day return of +49.3% (poorly timed on average, as stock subsequently rose), but at SION specifically his one prior measurable buy on 2025-02-10 declined 31.6% over 90 days; his three most recent SION sales in late November showed small 30-day negative returns but do not yet have 90-day outcomes. The company carries a net loss of $-20,278,000.00, which provides context for ongoing equity activity by insiders.

Director Peter A. Thompson sold 108,073 shares (2.9% of holdings) for $4.8M at avg $44.55, near 52-week highs.

Thompson executed 3 separate sales over 2025-11-24 to 2025-11-26, totaling 108,073 shares for $4,814,204.82 at a blended average price of $44.55—within 0.6% of the 52-week high of $44.38. This leaves him with 3,596,886 shares post-transaction. The stock has risen 14.2% over 30 days and 70.3% over 90 days, placing the sales at historically elevated levels for the stock. His cross-ticker track record shows 12 prior sells with a 16.67% well-timed rate and +49.3% average 90-day return, meaning prior sales were typically followed by further gains rather than declines. At SION specifically, his single prior buy in February 2025 returned -31.6% over 90 days. The company is unprofitable (net income $-20,278,000.00) with a market cap of $1,954,294,626.52. The sales at peak valuation merit close investor scrutiny given the company's negative earnings backdrop and the timing relative to sharp recent appreciation.

Director Thompson sells 1,176,332 shares at $4.16 (CRVS down 59.6% from 52-week high of $9.56)

Thompson Peter A., a Director of Corvus Pharmaceuticals, sold 1,176,332 shares at $4.16 on 2025-06-27, reducing his holdings from 8,341,338 shares to 7,165,006 shares (a -14.1% reduction). This substantial disposition occurs in the context of significant stock deterioration: at the transaction price of $4.16, the stock already stood 56.5% below its 52-week high of $9.56, and has subsequently declined further to a current price of $3.86. Thompson's cross-ticker track record reveals that his 11 prior open-market sells achieved an average 90-day return of +54.4% and a 9.09% well-timed rate (where well-timed means the stock falls after the sale), suggesting this particular sale was not well-timed relative to his historical pattern: the stock has risen 20.2% over the past 90 days and 2.1% over the past 30 days post-transaction, moving against the directional pattern of his prior sales. The company context shows current net income of $15,193,000, though the firm was unprofitable over its most recent full fiscal year, indicating operational distress that may factor into a director-level decision to reduce exposure by nearly 15% of held shares.

Director Peter A. Thompson bought 496,771 shares (496.8K shares) at $20.13 for $10,000,000.23 at EWTX on 2025-04-03; stock now -68.6% from 52-week high at $11.51.

Director Thompson deployed $10,000,000.23 in two separate tranches totaling 496,771 shares at $20.13 on 2025-04-03, representing a substantial capital commitment to Edgewise Therapeutics. The transaction came as the stock has declined sharply: the current price of $11.51 is -68.6% from the 52-week high and -56.9% over the prior 30 days, indicating a significant recent sell-off. Notably, Thompson's prior purchase at EWTX on 2024-01-23 proved well-timed at the 90-day mark with a +37.1% return, though his broader cross-ticker buy track record shows more modest results (3 prior buys with average 90d return of +6.3%). The company remains unprofitable with a net income of $-34,129,000.00 over its most recent full fiscal year, and the timing of a $10M insider purchase during steep stock decline warrants investor attention to the underlying thesis and any material developments that may have prompted the transaction.

Director Peter A. Thompson buys 550,000 shares of SION at $18.00 ($9.9M) 2 days post-IPO, as 5 other insiders buy within 14 days

Director Peter A. Thompson purchased 550,000 shares at $18.00 on 2025-02-10, increasing his holdings to 3,704,959 shares (+17.4% vs pre-transaction holdings). This transaction occurs just 2 trading days after Sionna Therapeutics' recent listing, with the stock currently trading at $22.24. The material signal here is the concurrent insider buying activity: 5 other insiders purchased shares within the same 14-day window, creating a multi-insider cluster buy pattern immediately following the company's market debut. This coordinated accumulation by multiple company insiders within the first two trading days suggests institutional knowledge of the initial offering and subsequent demand at post-IPO prices. Note: This filing involves derivative-conversion activity; Table II derivative holdings are not yet available in the database, so the director's complete position may be larger than the 3,704,959 shares reflected in Table I.

Director Peter A. Thompson sold entire 83,695 share stake (83.7K shares) in SPRY at $13.00 on 2024-08-26, divesting $1,088,035.00 ($1.1M) position

Thompson liquidated his complete SPRY position of 83.7K shares just three days after initiating sales on 2024-08-23, totaling 100.0% of pre-transaction holdings. The timing occurs amid substantial recent momentum—the stock has appreciated 25.4% over 30 days and 54.2% over 90 days—yet the director executed the full exit at $13.00, below the current price of $13.74. This rapid multi-day liquidation pattern contrasts with his prior trading history: across all tickers, his 10 prior open-market sells showed an average 90-day return of +29.9% with a 0.00% well-timed rate, indicating those sales preceded gains rather than declines. At SPRY specifically, his prior buy on 2023-08-29 declined -24.5% over 90 days, and the recent cluster of four consecutive sales (2024-08-21 through 2024-08-23) followed by this final liquidation raises questions about his conviction at current valuations. The company posted -97.7% annual revenue decline and net income of $-12.5M against quarterly revenue of only $500.0K, signaling severe operational stress that may be driving the director's exit despite positive recent price momentum.